WHAT YOU SHOULD KNOW: We are initiating coverage on six companies that we believe are undervalued players in the cell...
Read More
PSMA Program P-PSMA-101 is a solid tumor autologous CAR-T product candidate being developed to treat patients with metastatic castrate resistant...
Read More
